Top 30 Pharma Companies In India

ALEMBIC

Board of Directors:

• Chairman and CEO: Mr Chirayu Amin
• Managing Director: Mr Pranav Amin
• Managing Director: Mr Shaunak Amin
  Mr R.K Baheti
  Mr K.G Ramanathan
  Mr Pranav Parikh
  Mr Paresh Saraiya
  Dr Archana Hingorani

Therapeutic Categories: Dermatology, Oncology, and Injectable
Formulations

Major brands:

Roxie. The “No. …Cloff. Cloff is a brand of Clarithromycin Vitaresp FX. Vitaresp FX is the “Most trusted brand of ENTs” Tetan.

Pharma Market Performance: 2019-20, the company posted consolidated a net profit of ₹829 crores, up 41 per cent from ₹584 crores in the previous year. Consolidated revenues from operations for the year stood at ₹4,606 crores (₹3,935 crores).

Incorporated in the year: Founded in 1907 having headquartered in Vadodara, Gujrat, India.

Address and Contact: Alembic Road, Vadodara – 390 003,
Gujarat, India
Phone : +91 – 265 – 228 0550, +91 – 265 – 228 0880
+91 – 265 – 300 7000
Fax : +91 – 265 – 228 1508, +91 – 265 – 228 4728
Email : infoal@alembic.co.in

Alkem

Alkem Laboratories have 21 manufacturing facilities at multiple locations in India and the United States of America. Alkem Laboratories has over 800 brands with a 14500 plus strong workforce who have its business footprints in over 50 countries.

Board of Directors:

Executive Chairman: Mr Basudeo N. Singh.
Managing Director: Mr Sandeep Singh.
Joint Managing Director: Mr Dhananjay Singh.
Executive Director: Mr Balmiki Prasad Singh.
Executive Director: Mr Mritunjay Kumar Singh.
Independent Director: Mr Arun Kumar Purwar,
Independent Director: Mr. Ranjal Laxmana Shenoy.
Independent Director: Ms Sangeeta K. Singh.
Independent Director: Ms Sudha Ravi.
Dr Dheeraj Sharma.

Therapeutic Categories:

Anti-infective, Gastroenterology, Pain
Relief/Analgesic, Anti-diabetic, Cardiology, Dermatology,

Neurology/Central Nervous System (CNS) and Vitamins, Minerals &
Nutrients.

Major brands:

Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst the top 50 pharmaceutical brands in India.

Pharma Market Performance:

Consolidated revenue at Rs.73,572 Mn. for FY
2018 – 19. Alkem Laboratories have crossed the US $ 1 billion in 2019. In 2020.
ALkem Laboratories is one of India’s largest generic and speciality
pharmaceutical company.

Incorporated in the year: Alkem Laboratories was founded on year 1973.

Address and Contact: Devashish Building, Alkem House,
Senapati Bapat Road, Lower Parel,
Mumbai – 400 013.

E-mail: contact@alkem.com
Tel: +91 22 3982 99 99

Cadila Pharmaceuticals Ltd.

Board of Directors:

• Pratima Ram
• Professor Khandwalla
• Maj. General Khurana
• Amitava Mukherjee
• Girdhar Balwani
• Dr Rajiv I. Modi
• Ramesh Choksi
• Dr Abhijat Sheth
• Dr Ajit Singh
• Jaswinder Matharu

Therapeutic Categories:

Respiratory, diabetology, gastroenterology, pain management (antimigraine), orthopaedics. Anti-depressant, Anti-diabetic,
Anti-emetic, Anti-histaminic, Anti-hyperlipidemia, Anti-hypertensive,
Anti-inflammatory, Anti-osteoporotic, Anti-psychotic, Anti-thrombotic,
Anti-tuberculous, Cardiotonic, Cardiovascular, Disinfectant, Disinfectant,
Erectile dysfunction, Gastroprokinetic.

Major brands:

Haem Up, Cadiphylate, Ocupres, Lorfast
Meltab, Dexona Eye/Ear, Ocid,  Envas.

Pharma Market Performance:

The company is one of the leading pharmaceutical companies in India, with total revenue of ₹7,104.30 crores (US$1.0 billion) in 2019. It is a manufacturer of generic drugs.

Incorporated in the year: Founded: 1951

 Address and Contact: Sarkhej-Dholka Road, Bhat, Ahmedabad, India,
382210
+91 2718 225039
+91 2718 225001

Cipla Limited 

Cipla’s quality centres follow systematic interventions that consistently
meet and exceed quality standards. They ensure a culture of compliance and follow the highest standards in terms of quality control, compliance and adherence to quality guidelines and guidelines.

Board of Directors:

• Vice-Chairman: MK Hamied
• Independent Director: Adil Zainulbhai
• Independent Director: Naina Lal
• Managing Director & Global CEO: Umang Vohra

Therapeutic Categories:

Forty years ago, Cipla began its mission of combating heart disease with innovative, world-class drugs. Over the years, we have developed several products that have contributed to the prevention, treatment and treatment of heart diseases such as heart attack, stroke, diabetes and cancer. Other Therapeutic areas are HIV, oncology, and respiratory.

Brands:

The brands associated with the company are MHRA, US food and Drug, Health Canada, ANVISA, MCC, Invima, and others.

Market Performance:

The company’s annual revenue was $2.3 billion in 2014, up from $1.2 billion the year before, according to its most recent financial report. Cipla has expanded significantly over the past five years and is now India’s third-largest pharmaceutical company, according to the company’s annual financial report. With 48% of its exports from India, it represents more
than a third of the country’s total pharmaceutical exports and has 34 manufacturing facilities in 8 locations across India. Of IPM’s 300 leading brands, 22 have a market share of at least 20% in the US market. With worldwide sales of over 1.2 billion US dollars in 2014 and 2.3
billion US dollars worldwide, the company is the market leader in respiratory diseases and urology.
Licensing revenues from Cipla contributed 0.40% to total revenues for the quarter ended March 31, 2020. Scrap contributed 1.5% to total sales for the year ending March 31, 2019, and 1% for the first quarter of 2020.

Incorporates in the year:

2019:

• Received The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting.

• ‘Innovative Project of the Year’ for the IT-OT Security Convergence Program. 

• Golden Peacock Award for CSR in recognition of Cipla Foundation’s significant contribution towards social change.

2020:

• Best Innovative Use of Technology in Procurement’ and ‘Supply Chain People Development” at the Cargo Connect Awards
• What’s Up Cipla bags the ‘Best Small Idea, Big Impact Communication of the Year’ at the Corp Comm & PR Excellence Awards
• Received exchange4media Health Marcom Awards

• Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain

PRISM Award for #FafChallenge campaign by Cipla South Africa

Contact Details: 
Cipla House, Peninsula Business Park, 
Ganpatrao Kadam Marg,  Lower Parel, Mumbai-400013
Contact Numbers: +91 22 24826000 / +91 22 24826701
+91 22 24826300
Reference:
www.cipla.com
economictimes.indiatimes.com

DR REDDY’S LABS

All logo rights reserved with Dr. Reddy Laboratories

The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.

Board of Directors:

Co-Chairman & MD: G. V. Prasad

Chairman: Satish Reddy

Chief Executive Officer: Erez Israeli

Chief Financial Officer: Saumen Chakraborty

Therapeutic Categories:

The company focus on therapeutic areas such as Oncology, Gastroenterology, Cardiovascular, Anti-Diabetic, Dermatology, and Pain Management, Dental, Nephrology and Urology.

Brands:

The top brands associated with the company are Nise, OMEZ, Stamlo, Clamp, Econorm, Razo, SENQUEL-F, KETOROL, ATOCOR, MINTOP, VENUSIA, Glimy, and Telsartan Active.

Market Performance:

The Return on Capital Employed (ROCE) stands at 14.7% higher than FY 18 and FY 17 and this symbolizes how efficiently the company has utilized the capital and generated profits.
The Net Debt to Equity Ratio has reduced to 0.09 from 0.24 signifying the financial stability of our business. New markets entered in this reporting year – Thailand, Malaysia and Indonesia. The Company’s total sales included: (1) pharmaceuticals, which contributed 98.50% of total sales; (2) services, which contributed 0%; (3) service revenues, which contributed 1%; and (4) other operating income, which contributed 2% for all years ended on or after March 31, 2019. The scrap, which contributed 0.15% of total sales; consumed chemicals, which contributed 0.33% of total sales; and royalties, which contributed 1.52 % of total sales.

Incorporates in the Year:

2008:

• Gold Shield – ICAI Awards for Excellence in Financial Reporting
• Best CSR & Sustainability Practices, 9th International Conference on Corporate
• Governance & Sustainability
• RedituxTM – ‘Product of the Year
• IT User Award at NASSCOM-CNBC IT User Awards
• Unichem Generics Supplier Award (UK)

2009:

• Received Prestigious AIF – Annual Spring award
• Received 3 Awards  for Best All India  House Journal
• Five awards including Overall Excellence Award for Communications
• Collaterals
• BEST Company in Class with sales under $100 M USD

2017:

• Dr Reddy’s wins” Sakshi Excellence awards 2017” for two of its CSR programs i.e. Excellence in Education for School Improvement Program (SIP), and Excellence in Health Care – for Community Health Intervention Program (CHIP).

2018:

• Dr Reddy’s received the ‘Top 50 Pharma Innovation Award’ at the Pharma Gorilla Conference in Singapore.
• The R&D team received a certificate of appreciation from ITC-Wow, a nationwide recycling initiative.
• Dr Reddy’s won the Excellence in Sustainable Packaging –Packaging Team of the Year award at India Packaging Awards by UBM.
• Dr Reddy’s wins award for Innovative Talent Management and Succession Planning at the JobBuzz New-Age Workplace.

2019:

• The company was declared the API Supplier of the Year at the Global Generics & Biosimilar Awards held in Frankfurt. 
• Dr Reddy’s won the “Sustainable Organization of the Year 2019 – Pharma Sector” award at the India Sustainability Summit.
• Dr Reddy’s was conferred with the India Pharma Corporate Social Responsibility (CSR) Program of the Year award by the Ministry of Chemicals and Fertilizers, Govt. Of India.

Reference:
https://www.drreddys.com/media/826252/sustainability-report-18-19.pdf
https://economictimes.indiatimes.com/dr-reddy’s-laboratoriesltd/stocks/companyid-13841.cms
https://en.wikipedia.org/wiki/Dr._Reddy%27s_Laboratories#Global_expansionhttps://www.drreddys.com/contact-us/global-locations/

Emcure Pharmaceuticals Private Limited

Board of Directors:

• Independent Director: Mr Humayun Dhanrajgir
• Independent Director: Mr Shreekant Krushnaji Bapat

• Mr Berjis Minoo Desai
• Mr Samonnoi Banerjee
• Mr Satish Ramanlal Mehta
• Dr Mukund Keshao Gurjar
• Mr Sunil Mehta
• Mrs Namita Thapar

Therapeutic Categories:

Blood-related, cardiology, pain and analgesics, HIV, gynaecology, nephrology, anti-infective, vitamins, minerals and nutrients products. Recently entered the oncology, diabetes and neuroscience therapeutic areas.

Major brands:

• Orofer XT (Haematologics/ iron preparations)
• Bevon
• Vintor (blood related)
• Orofer S (Haematologics/ iron preparations)
• Asomex (cardio/ anti hypertension)
• Metpure XL (cardio/ anti hypertension)
• Augpen (antibiotics)
• Zostum
• Eman Zen
• Maxtra

Pharma Market Performance: Ranked as the 12th largest pharmaceutical company
Incorporated in the year: Emcure Pharmaceuticals Private Limited was
incorporated on April 16, 1956.

Address and Contact: Emcure House, T 184, M.I.D.C.,
Bhosari, Pune 411 026.
Tele: 020-30610000
Fax: 020-30610111
Mail:  Corporate@emcure.co.in

Eris Lifesciences

Board of Directors:

• Mr. Amit Bakshi
• Mr. Inderjeet Singh Negi
• Ms.Vijaya Sampath
• Dr. Kirit Nanubhai Shelat
• Mr. Prashant Gupta

Therapeutic Categories:

Cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.

Major brands:

Glimisave, Eritel, Olmin, Tendia, Renerve,Remylin, Rabonik, Tayo, Lnbloc, Cyblex, Atorsave, Rosiflex, Crevast, Raricap, Serlift.

Pharma Market Performance:

• Eris has outpaced the Indian Pharmaceutical Market (IPM) growth with a CAGR of 19.7% in Chronic+Subchronic and 13.7% in Acute therapy segment.

• In 2019-20, the net profit of the company stood at Rs 296.29 crore as against Rs 291.14 crore a year ago, the filing said. Revenue from operations in the last financial year was Rs 1,074.05 crore.

Incorporated in the year:

The Company was incorporated as “Eris Lifescience Private Limited” on January 25, 2007, as a private limited company under the Companies Act 1956, at Ahmedabad, with a certificate of incorporation granted by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli.

Address and Contact: 8th  Floor, Commerce House IV, Prahladnagar,
Ahmedabad – 380015 Gujarat, India.
Phone : +91-79-30451111
Phone : +91-79-71841000
Phone : +91-79-71841001
Phone : +91-79-71841198
Email: info@eris.co.in

FDC Limited

Board of Directors:

• CA. Uday Kumar Gurkar
• Mr. Mohan A. Chandavarkar
• Mr. Nandan M. Chandavarkar
• Mr. Ashok A. Chandavarkar
• Mr. Ameya A.
• Chandavarkar
• Ms Nomita R. Chandavarkar
• Mrs Swati S. Mayekar
• Mr. Melarkode Ganesan Parameswaran
• Dr. Mahesh Bijlani
• Ms. Usha Athreya Chandrasekhar

Therapeutic Categories:

Anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, analgesics.

Major brands:

FDC’s  Zifi, Electoral,  Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm are leading brands in their respective segments in India.

Pharma Market Performance:

Incorporated in the year:

In 1940, this partnership firm was incorporated as a private limited company – Fairdeal Corporation (Private) Limited and in 1986 its name was changed to FDC Private Limited.

Address and Contact:

Address:

FDC LIMITED, B-8, MIDC Area
Waluj – 431 136
Dist. Aurangabad
Maharashtra

Tel: 0240 – 2554407 / 2554299 / 2554967
Fax: 0240 – 2554299

FRANCO INDIAN PHARMA

Board of Directors:

• Mr. Pascal Postel
• Mr. L. B. Yadav
• Dr. J. P. Mehta
• Mr. D. R. Sinha

Therapeutic Categories:

OHAs, Respiratory, Hepatoprotective, Gynaecological, Paediatric, Antioxidants and Dermatologicals in multiple forms including tablets, capsules, creams, ointments, solutions and suspensions.

Major brands:

DEXORANGE (Hematinic), GLYCIPHAGE Range (Anti-
diabetic), GRILINCTUS (Cough preparation), GRILINCTUS BM Syrup
(Cough preparation), SORBILINE (Digestive and Liver disorders), SURFAZ SN (Dermatological).

Pharma Market Performance:

• FIPPL has been consistently ranked as one of the most reputed companies and is among the top 35 Pharmaceutical Companies according to the 2012 AIOCD Pharmatrac ranking.

• Franco-Indian Pharmaceuticals Private Limited’s operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2018. It’s EBITDA has increased by 17.06 % over the previous year. At the same time, it’s book networth has increased by 39.86 %.

Incorporated in the year: (FIPPL), founded in 1949

Address and Contact:

Head Office
20, Dr. E. Moses Road
Mahalaxmi
Mumbai – 400 011
Phone: 022 – 24934026 / 27 / 30
Fax: 022 – 24920557
Email: customercare@francoindian.com

Himalaya Drug

Board of Directors: Syed Farooq Ahmed, Syed Farooq
Ahmed, Jayashree Ullal, Philipe Joseph Haydon
and Meraj Alim Manal.

Therapeutic Categories:

Major brands: Koflet-SF lozenges, Septilin, Confido, Himalaya PureHands Advanced, Tentex Forte, Ophthacare Eye Drops, Himcolin Gel, Liv.52 DS, Tentex Royal, Liv. 52,
Koflet H Lozenges, Abana.

Pharma Market Performance:

Incorporated in the year: The Himalaya Drug Company is an Indian company established by Muhammad Manal in 193

Address and Contact: The Himalaya Drug Company,
Makali, Bengaluru – 562162
Call Us: 1–800–208–1930

IPCA LABS

Board of Directors:

• Chairman and Managing Director: Premchand Godha
• Ajit Kumar Jain
• Pranay Godha,
• Prashant Godha
• Anand T. Kusre
• Dev Prakash Yadava
• Dr. Manisha Premnath
• Kamal Kishore Seth

Therapeutic Categories: NF

Major brands: Leading brands in Pain, Rheumatology, Antimalarials and
Hair care therapy in India

Pharma Market Performance: Revenue: 1,559 crores INR (US$220
million)

Incorporated in the year: Founded: 19 October 1949

Address and Contact: 125, Kandivli Industrial Estate, Kandivli (West),Mumbai 400 067, Maharashtra, India.
Tel: +91 (22) 6210 5000

Lupin

Board of Directors:

• Chairperson (Non Executive): Mrs. Manju D Gupta
• Vice Chairman (Non Executive): Dr. Kamal K Sharma
• Chief Executive Officer: Ms. Vinita Gupta
• Managing Director: Mr. Nilesh Deshbandhu Gupta
• Executive Director: Mr. Ramesh Swaminat
• Independent Director: Mr. R A Shah
• Independent Director: Mr. Rich
• Independent Director: Dr. K U Mada
• Independent Director: Dr. Dilip C Choksi
• Independent Director: Mr. Jean-Luc Belingard
• Independent Director: Ms. Cristine Mundkur

Therapeutic Categories:

Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. In  addition to this,
Anti-Diabetic, Neuro/CNS and Gynaecology space are being improved and market growth is achieved in the Respiratory, Anti-Diabetic and Gynaecology therapeutic areas.

Brands:

The brands associated with the company are US Food and Drug, Medicines and Healthcare Products Regulatory Agency, Ministry of Health, Labor and Welfare, Australian Government, WHO and mcc.

Market Performance:

Despite the challenges of high production costs, limited availability of raw materials and limited capacity in the supply chain, Lupin’s India business is a dynamic front runner. For the year ended March 31, 2019, revenue from domestic prescriptions totaled $1.2 billion, representing market growth of 6%, compared to a global average of 4.5% for the same period in 2018. With a market share of 3.6%, Lupin’s India business can maintain its 5th
place in the Indian pharmaceutical market (IPM) each year, grow fastest and continuously surpass the IPM among the top 5 companies. Lupine continues to be the leader in the anti-TB segment and occupies 3rd place in anti-diabetes therapy.

Incorporates in the year:

2011:

• The company was ranked 2 nd among Inida’s best company to work for in the biotechnology and pharmaceutical sectors.
• Healthcare Distribution Management Solution (HDMA) offers Lupin for DIANA Award for best overall product generic manufacturer.

2012:

• Won the NDTV business leadership award.
• Mr. Ramesh Swaminathan won te Business Today Yes Bank for Best CEO Award.
• Lupn Bags ‘Niryat Shree ‘ Gold Trophy for outstanding export performance in the category of chemicals, drugs, pharma and allied products.

2015:

• Won India’s Risk Management Award at CNBC TV18.
• Lupin #1 in pharma in ‘Best at Investors Relation’ by Finance Asia, 5 th in overall ranking.

2016:

• Golden Peacock Award for excellence n corporate governance
• Ranked 15th in the great places to work, best companies to work for in Asia.

2017:

• Walmart Supplier of the World Award
• Best Award from ATD

2018:

• Crystal Globe Recognition Award, 2 nd time in the row.
• Receives Prstigious Annual Innovator Award from BioNJ, New Jersey.

2019:

• Siver Award for Lean Six Sigma project fro0m OCFI.
• Mc Kesson Supplier of the Award in US.
• Theree of the manufacturing sites Ankleshwar, Mandideep and Tarapur are at level 7 of ISRS 8th edition, the highest safety rating to be received by pharmaceutical organization.

2020:

• Lupin Ankleshwar Facility wins Gold Award from American society for quality.
• India Pharma Leader Award.

Contact Details:
Harborplace Tower,
111 S.Calvert Street,
21st floor Baltimore,
MD 21202.
By Phone
410-576-2000
Reference:
https://www.lupin.com/

Macleods

All logo rights reserved with Macleods

Macleods is currently ranked 10th in Indian Pharmaceutical Industry and is
recognized as one of the fastest growing pharmaceutical company in India.
Pioneering efforts of Macleods in providing medications for both chronic and acute therapy.

Board of Directors:

• Banwarilal Murlidhar Bawri
• Girdharilal Murlidhar Bawri
• Rajendra Murlidhar Agarwal
• Vinayak Vasudev Shirodkar
• Ruchi Rajendra Agarwal
• Ashok Anant Mahashur
• Mihir Bipin Shah
• Suvarna Dadabhau Gholap

Therapeutic Categories:

TB, malaria & HIV. Cardiovascular, Diabetes,
Orthopedics, Gynecology, Respiratory and Oncology.

Major brands:

Macromycin, Zicoplanin, Macrozide,
Famcimac, Maclitaxel, Maxolid, Maxlolid-Ds, Matrix.(Google)

Pharma Market Performance:

Macleods has enjoyed rapid growth in the recent years, growing at an average growth rate of over 22% for the past 5 years.

Incorporated in the year:

Macleods Pharmaceuticals Ltd, was incorporated on 05 June, 1989.

Address and Contact: Atlanta Arcade, Marol Church Road, Andheri (East),
Mumbai – 400059, India.
Tel : +91-22-6676-2800
Fax : +91-22-2925-6229

Email: exportsmacleodspharma.com/ customercare@macleodspharma.com

Mankind Pharma

All logo rights reserved with Mankind Pharma

Board of Directors:

• Mr. Rajeev Juneja, the CEO of Mankind Pharma
• Mr. P.K Arora, Director
• Mr. Sheetal Arora, Managing Director
• Mr. Arjun Juneja, Director

Therapeutics Categories:

Therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

Major Brands:

Manforce Condom & Preganews are the flagship brands leading their
respective categories. Other brands like Unwanted72, Acnestar & Gasofast hold a significant share & are popular brands.

Pharma Market Performance:

The total net worth of Mankind Pharma’s products are as follows:  Telmikind (Rs. 2644 million), Moxikind-CV (Rs. 2175 million), Amlokind (Rs.1903 million), Nurokind (Rs. 1322 million), Cefakind (Rs. 950 million)  and Zenflox (Rs.781 million).

Incorporated in the year: Mankind Pharma came into existence in 1986 and in 1991, the company was formed into a legal corporation.

Address and Contact: 208, Okhla Industrial Estate Phase 3 Rd, Okhla Phase III, Okhla, Industrial Area, New Delhi, Delhi 110020.

Website: www.mankindpharma.com

Email: contact@mankindpharma.com
Ph.: (+91)-11-46541111 (30 Lines)
Fax: (+91)-11-46541382

Micro Labs Limited

All logo rights reserved with Micro Labs Limited

It is ranked amongst top 19 in India with a market share of 1.95% as per
AIOCD-AWACS July 2019.The group has presence in over 40 countries,with ground level operations in 15 countries, exporting all major dosages in every therapeutic segment.

Board of Directors: Mr Dilip Surana, Mr Anand Surana

Therapeutic Categories: Fever & pain management, anti-infective, anti-
allergics, gastroenterologicals, anxiolytics, hepatoprotectives, paediatric
and Gynaecological segments.

Cardiology, Diabetology, Pain management, Dermatology, Veterinary,
Neurology, etc.

Major brands:

Dolo-650, Dolowin range, Esofag-D, Ebast, Anxit,
Silybon, Gramocef-CV and Microdox-LBX.

Pharma Market Performance:

Micro Labs is a multi-faceted organization with an annual turnover of Rs.2700 crore, including exports that contribute Rs. 920 crore.
The glittering stars of the company are 14 oral formulation plants
including an injectable unit; a bulk drug facility, offices located overseas,
and a strong distribution network. Our marketing efforts span into
20 divisions, with each division specialized to cater to various therapeutic
segments.

Incorporated in the year:

Micro Labs Private Limited was founded in
1973 at Madras (now known as Chennai)
Address and Contact: Corporate Address
MICRO LABS LIMITED
31, RACE COURSE ROAD,
BANGALORE-560 001, INDIA
 +91-80-2237 0451-57
 +91-80-2237 0463

Merck Sharp & Dohme (MSD)

All logo rights reserved with Merck Sharp & Dohme (MSD)

Board of Directors:

• Kenneth C. Frazier
• Leslie A. Brun
• Thomas R. Cech,
• Mary
• Ellen Coe
• Pamela J. Craig
• Thomas H. Glocer
• Risa J. Lavizzo-Mourey
• Paul B. Rothman
• Patricia F. Russo,
• Christine E. Seidman
• Inge G.
• Thulin
• Kathy J. Warden
• Peter C. Wendell

Therapeutic Categories:

Metabolics, Vaccines, Critical Care, Oncology,
Women’s Health, Dermatology, Respiratory, and Primary Care. cardiovascular, diabetes, obesity, bone, respiratory, immunology, dermatology, infectious disease, oncology, neurosciences, ophthalmology, women’s health and endocrinology.

Major brands:

Janumet, Januvia, RotaTeq, Pneumovax 23, Temodal ,
Keytruda, Emend Oral, Emend IV , Janumet  XR CP, Gardasil , Zostavax ,Variped

Pharma Market Performance: MSD announced first-quarter sales of $10.8 billion worldwide – an increase of 8%, including a 3% negative impact from foreign exchange. The company anticipates full-year 2019 revenue range to be between $43.9 billion and $45.1 billion, including an approximately 1% negative impact from foreign exchange.

Incorporated in the year:

Address and Contact: 000 Galloping Hill Road
Kenilworth, NJ 07033 U.S.A.

Phone: 908-740-4000

Novartis International 

All logo rights reserved with Novartis International

Board of Directors:

• Joerg Reinhardt, Chairman
• Enrico Vanni, Vice Chairman
• Nancy C. Andrews
• Ton Buechner
• Patrice Bula
• Srikant Datar
• Elizabeth Doherty
• Ann Fudge
• Bridgette Heller
• Frans van Houten
• Simon Moroney
• Andreas von Planta
• Charles L. Sawyers
• Williams T. Winters
• Charlotte Pamer- Wieser

Therapeutic Categories:

Cardiovascular-metabolic, Ophthalmology, Respiratory, Neuroscience, Immunology and Dermatology, Oncology, Cell and Gene Therapy.

Major brands:

Cosentyx, Gilenya, Lucentis, Tasigna, Entresto,
Sandostatin, Afinitor/Votubia, Promacta/Revolade, Tafinlar + Mekinist,
Galvus Group, Gleevec/Glivec, Xolair, Jakavi, Diovan Group, Exforge
Group, Exjade/Jadenu, Votrient, Ilaris, Zortress/Certican, Kisqali.

Pharma Market Performance:

Novartis reported earnings of US$11.732 billion, with an annual revenue of US$48.677 billion, an increase of 5.59% over the previous fiscal cycle. Novartis shares traded at over $88.14 per share, and its market
capitalization was valued at $205.32B as of April 28, 2020.

Incorporated in the year:

Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz and has a rich history spanning over 200 years.

Address and Contact: Basel, Switzerland
Tel: +41 61 324 11 11
Fax: +41 61 324 80 01
(Switzerland)

Address and Contact: Basel, Switzerland
Tel: +41 61 324 11 11
Fax: +41 61 324 80 01
(Switzerland)

Sanofi

All logo rights reserved with Sanofi S.A.

Sanofi is present in 100 countries having 73 manufacturing sites in 32
countries and providing healthcare solutions in more than 170 countries
around the world.

Board of Directors:

• Chairman: Serge Weinberg
• Chief Executive Officer: Paul Hudson
• Director: Laurent Attal

Therapeutic Categories:

Cardiovascular, central nervous system, diabetes, internal
medicine, oncology, thrombosis and vaccines (it is the world’s largest
producer of the latter through its subsidiary Sanofi Pasteur).

Major brands:

Adenocor, Aldurazyme, Lantus, AllStar, Amaryl
MP, Amaryl M, Amaryl M Forte, Amaryl MV, Apidra, Arava,
Aubagio, Augeoz, Brodactam, Cardace, Cardace Protect, Cardace
AM, Cardace H, Cardace Meto, Caspercid, Cerezyme, Cetapin P,
Cetapin XR, CetapinV, Clexane, Cordarone, Cordarone / Cordarone
X, Daonil, Daonil M, Depakote, Depakote XR, Fabrazyme,
Fasturtec, Fludara, Frisium, Insuman Rapid, Insuman Comb 25,
Insuman Comb 50, Jevtana, Lantus, Lasilactone 50, Lasix, Lasix,
Lyxumia, Metosan XR, M-Nem , Myoril, Myoril, Myozyme,
Plavix ETC.

Pharma Market Performance:

More than 4.5 billion units of pharmaceuticals, consumer healthcare and vaccines sold in 2019.

Net sales were €36,126 million, up 4.8% on a reported basis and 2.8% at CER (up 3.6% at CER/CS (4) ) in 2019.

Incorporated in the year:

Sanofi was incorporated under the laws of France in 1994, as a société anonyme, a form of limited liability company.

Address and Contact: Investor Relations
54, rue La Boétie
75008 Paris
France.
Phone: +33 (0)1 53 77 45 45
E-mail: IR@sanofi.com

Sun Pharma

It was established by Mr. Dilip Shanghvi in 1983. Today, it is the largest chronic prescription company in India.

Board of Directors:

• Chairman: Israel Makov.  Dilip Shanghvi
• Managing Director: Sudhir V. Valia
• Managing Director: Sailesh T. Desai
• Executive Non-Independent Director: Kalyanasundaram Subramanian
• Non-Executive Independent Director: Vivek Chaand SehgalRekha
• Non-Executive Independent Director: Gautam Doshi

Therapeutic Categories:

The company offers formulations in various therapeutic areas, such
as cardiology, psychiatry, neurology, gastroenterology and diabetology. Other therapeutic area are CNS, CVS, Women Health, Dermatology, Ophthalmology, Oncology, Anti-Infectives and Gastro therapies.

Brands:

The major brands associated with the company is Ranbaxy, Ocular Technologies, In Site Vision, Opiates business of GSK, pharmalucence, URL pharma, DUSA Pharmaceuticals Inc., MSD, CARACO, TARO, chottem chemicals inc., ABLE laboratory Inc. and others.

Market Performance:

With global revenues of over US$ 4.5 billion, Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries worldwide.
Sun Pharma is also India’s largest and pharmaceutical company. The global presence is supported by over 40 manufacturing facilities across six continents. Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 50% turnover. The Indian pharmaceutical
industry has become the third-largest producer in the world in terms of volumes and is poised to grow into an industry of $36.7 billion from $20 billion.

In corporate in the year:

2012:

• Awarded as most outstanding company of the year CNBC TV18
• Listed among the world 100 most innovative companies by Forbes

2013:

• Named as company of the year by Economic Times

2014:

• Receives Cardiovascular Company of the Year Award by Frost & Sullivan.

2015:

• Excellence in CSR Award by India Pharma Awards 2015, instituted by UBM-India.
• India Pharma Research & Development Award 2015 by Ministry of Chemicals & Fertilizers, Government of India.

2016:

• Sun Pharma receives Community Care Award by ASSOCHAM (Associated Chambers of Commerce).
• Sun Pharmaceutical Industries Inc. receives DIANA (Distribution Industry Award for Notable Achievements) Award by Healthcare Distribution Alliance, USA.

2018:

• Receives Outstanding Contribution in CSR by Federation of Gujarat Industries
• Receives Best CSR Practices by The Economic Times (ET).

Contact Details:
2 Independence Way,
Princeton,
NJ 08540
(609)720-9200 (609)514-1155
Reference:
sunpharma.com
en.wikipedia.org

Torrent Pharmaceuticals Ltd. 

The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.

Board of Directors:

• Chairman Emeritus: Shri Sudhir Mehta
  
• CEO and Executive Chairman: Shri Samir Mehta
• Director: Shri Shailesh Haribhakti
• Director R&D: Dr. Chaitanya Dutt
• BOD: Ms. Ameera Shah
• BOD: Ms. Nayantara Bali
• BOD: Shri Haigreve Khaitan
• BOD: Shri Jinesh Shah

Therapeutic Categories: Cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC)

Major brands:

Lamitor-Od, Toraft, Shelcal, Esperal, Chymoral Forte, Evalon, Domstal, Droxyl, Thioril, Trinicalm, Antidep, Licab, Valparin Alkalets.

Pharma Market Performance:

Revenues in India was 3234 Cr. in 2018 –2019 Torrent Pharma reaches the target market segments through 23 sales division with a wide customer coverage through 5000+ stockists and 59000 retailers serviced through 22 distribution centres across India.

Torrent Pharma also has a strong international presence spread across 40
countries with operations in regulated and emerging markets like US, Europe, Brazil and Rest of the World. The Company operate through its wholly-owned subsidiaries spread across 12 nations with major setups in Brazil, Germany and the US.

Incorporated in the year: Torrent Pharmaceuticals was founded in the year 1959.

Address and Contact: Torrent House, Off. Ashram Road, Ahmedabad –
380009, Gujarat, India.

Phone No. : +91-79-26599000, Fax No: +91-79-
26582100.

USV

Board of Directors:

Chairperson: Leena Gandhi Tewari
Managing Director: Prashant Tewari
Director: Debabrata Bhadury
Director: Deepak Ghaisas
Director: M. M. Venkatachalam
Executive Director & COO: Jayant Dwivedy
Director: Vilas Gandhi Tewari

Therapeutic Categories:

• Diabetes
• Cardiovascular
• Vitamins / Nutritional / Minerals
• Gastro-Intestinal
• Dermatology/Cosmetology
• Gynaecology
• Paediatrics
• CNS
• Anti-Infectives
• Anti-Hemorrhoids
• Respiratory

Major brands: Glycomet GP, Jalra-M, Ecosprin AV, Glycomet, Glycomet
The trio and Ecosprin Gold, Glycomet, Glycomet GP, Pioz, Pioz MF,
Glynase, Glynase MF and Glycomet Trio, Ecosprin, Ecosprin Gold,
Ecosprin AV and Nimodip, Derobin, Aquasol A, M.V.I, Anovate.

Pharma Market Performance:

In the financial year 2019-20, our total income was Rs 33,080 million. Our Indian business contributed 85% to the revenue and the rest was from the export of APIs and Finished Dosages.

Incorporated in the year: Founded in the year 1961 having headquartered In Mumbai.

Address and Contact: BSD Marg, Station Road, Deonar, Govandi East,
Mumbai, Maharashtra 400088.

Tel: +91-22-2556-4048 & 6786-1111
Fax: +91-22-2558-4025.
EMAIL ID: info@usv.in

Wockhardt

Wockhardt is a true Indian Multi-National Company with a multi-ethnic
the workforce of 8600 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.

Board of Directors:

Dr. Habil Khorakiwala
Dr. Huzaifa Khorakiwala
Dr. Murtaza Khorakiwala
Mr. Aman Mehta
Mr. D S Brar
Dr. Sanjaya Baru
Mrs. Tasneem Mehta
Mr. Vinesh Kumar Jairath
Ms. Zahabiya Khorakiwala
Mrs. Rima Marphatia

Therapeutic Categories:

• Anti-Infectives
• Cardiology
• Dermatology
• Diabetology
• Neurology
• Pain Management
• Respiratory

Major brands: Aceroc, Ace Proxyvon, Biovac-B, Brozedex, Clopione,
Cavidin INH, Gainehair Solution, Viscodyne and Zedex

Pharma Market Performance: The Company has a market capitalisation of over ₹211 billion (US$3.0 billion) and an annual turnover of ₹36
billion (US$500 million).

Incorporated in the year: Wockhardt was founded by Dr Habil Khorakiwala in the 1960s. His father Fakhruddin T. Khorakiwala had acquired Worli Chemical Works in 1959. This was incorporated as Wockhardt Pvt. Ltd., in 1973. Wockhardt Ltd. was incorporated on July 8.1999.

Address and Contact: Wockhardt Towers
Bandra Kurla Complex, Bandra (East)
Mumbai 400051
Maharashtra, India
Tel: +91 22 2653 4444
Fax: +91 22 2652 3905

Zydus Cadila

Board of Directors:

Chairman: Pankaj R. Patel

Managing Director: Dr.Sharvil P. Patel

Director: Mukesh M. Patel

Director: Dharmishtaben N. Raval

Director: Bhadresh Shah

Director: Nitin Raojibhai Desai

Director: Apurva S. Diwanji

Director: Ganesh N. Nayak

Therapeutic Categories:

Major brands:

Grd, Sugar Free, Ciprobid Eye Drops, Depten,  Dietmann, Tramazac, Epsolin

Pharma Market Performance:

From a humble turnover Rs. 250 crores in 1995 the group witnessed significant financial growth and registered a turnover of
over Rs. 14,253 crores in FY20.

Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Incorporated in the year: The origin of the company dates all the way back to
the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B.
Patel (late)

Address and Contact: Plot No. 103, Nr. Nirma University, Mouje- Khoraj, Sarkhej- Gandhinagar Hwy, Ahmedabad, Gujrat 382481.